source
- Argenx acquires Unnatural Products for up to $1.15 billion to boost oral peptide platformArgenx announced it will buy biotech Unnatural Products, paying $550 million upfront with the total deal value potentially reaching $1.15 billion through development and regulatory milestones. The…
- Phase II success does not guarantee easy Phase III launch, says Thermo FisherPositive Phase II data often signals the start of Phase III planning, but the transition involves far more than simply adding patients and sites. When a trial expands into new countries, differenc…